Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

s and the potential to generate near-term revenue through product sales or royalties for the approved indications in China while seeking global approval in new indications.

DelMar will continue the business of DelMar Pharmaceuticals (BC) Ltd., headquartered in Vancouver, British Columbia with clinical operations in Menlo Park, CA, as a subsidiary under the leadership of DelMar Pharmaceuticals (BC) Ltd.'s current management team, headed by Chief Executive Officer Jeffrey Bacha . In connection with the Acquisition, DelMar issued to the former shareholders of DelMar Pharmaceuticals (BC) Ltd. the equivalent of 13,070,000 shares of its common stock.  Details of the transaction will be filed on a Form 8-K with the United States Securities and Exchange Commission.

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be resold absent registration under or exemption from such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933.

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015 The South Dakota ... (ASU) have entered into an agreement to promote cooperation ... of agreement signed by the universities will encourage and ... and other services particularly, though not exclusively, relating to ... complementary strengths and a similar set of values,” said ...
(Date:4/24/2015)... April 24, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... as the supplier of bio-succinic acid used to ... for textile applications that Bayer MaterialScience has begun ... IMPRANIL ® eco, a series of bio-based ... as high as 65%.  IMPRANIL ® eco ...
(Date:4/24/2015)...  Navitas Life Sciences is delighted to announce the appointment ... Regulatory Services. Shalabh is a proven leader in Life Science ... Kinapse, as well as a Strategy consultant at Accenture. ... http://photos.prnewswire.com/prnh/20150423/201261LOGO ... delighted to welcome Shalabh into this critical role and also ...
(Date:4/23/2015)... Marshall, MN (PRWEB) April 24, 2015 ... agreement with Advanced Birthright Nutrition® (ABN) for the exclusive ... Milk Cup. The new technology is a new in-line ... swine producers by allowing them to move supplementation milk ... running. , “This technology lets producers get ...
Breaking Biology Technology:South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2Ralco Acquires License to Birthright™ Moveable Milk Cup 2
... - William Blair & Company 29th Annual Growth Stock Conference on ... Needham Life Sciences Conference on June 11 - , ... GPRO ) announced today that the Company will present at the ... at approximately 11:20 a.m. Central time (12:20 p.m. Eastern time) on ...
... Block The Attachment Of The Virus To The Nasal Membranes , ... Corporation (Pink Sheets: MNCN), an innovative, global wellness solutions company, announces ... hand carried and used as needed to form a mechanical barrier ... , , Peter Nash, Ph.D. and Chief Science Officer of ...
... June 4 Haemonetics Corporation (NYSE: HAE ) ... of Massachusetts has made a ruling in the Company,s lawsuit ... jury issued a verdict in favor of Haemonetics, finding that ... patent. The jury awarded Haemonetics $15.7 million in damages ...
Cached Biology Technology:Gen-Probe to Webcast Two Upcoming Investor Presentations 2Mach One Corporation Developing a Nasal, Hand Carried Product as Solution to Swine Flu (H1N1) Virus 2Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 2
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... you,ve owned a pet guppy, you know they often jump out ... jumped; many a parent has been stumped for an answer. ... how guppies are able to jump so far, and suggests why ... that controls animal behavior, decided to study jumping guppies while researching ...
... Electronics group have come up with a novel solution ... organic semiconductor industry today. Oana Jurchescu, an assistant professor ... high performance organic semiconductor ,spray paint, that can be ... This is a potentially game changing technology for a ...
... reduced mortality in a mouse model of the neurodegenerative ... according to a new study by researchers at the ... published online ahead of print in the journal ... for melatonin are found in the nerve cells, a ...
Cached Biology News:Why do guppies jump? 2High performance semiconductor spray paint could be a game changer for organic electronics 2Pitt team finds melatonin delays ALS symptom onset and death in mice 2
Applications: ISH...
... Immunogen: Recombinant human IDO ... for the ~44 kDa human ... (positive control: IFN-Gamma-stimmulated Human peripheral ... homology reactivity with mouse and ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: